Female patients with urge and urge incontinence who are candidates for the Altaviva implant will be enrolled and data collected.

Female patients with urinary incontinence and obesity will enter a phase 3, randomized, double-blind, placebo-controlled study to assess Berobenatide, Pfizer’s investigational ultra-long-acting GLP-1.